DDInter535 DDInter636
Diazoxide is a non-diuretic benzothiadiazine derivative that activates ATP-sensitive potassium channels.[A255647,L44612] It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. Diazoxide is commonly used in the treatment of hyperinsulinaemic hypoglycemia due to its ability to inhibit insulin release. Diazoxide also exhibits hypotensive activity and reduces arteriolar smooth muscle and vascular resistance. When administered intravenously, diazoxide can be used to treat hypertensive emergencies; however, this specific form of diazoxide is no longer available in the US. Diazoxide is usually well tolerated, and some of its more common side effects include fluid retention and electrolyte disturbances. In September 2015, the FDA issued a safety alert regarding post-marketing reports of pulmonary hypertension occurring in infants and neonates.[A255
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014. As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold). Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart failure regardless of ejection fraction.[L40783,L13916]
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Diazoxide {u} (Compound) binds {v} (Gene) KCNJ11
KCNJ11 {u} (Gene) is bound by {v} (Compound) Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vilanterol
Vilanterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methylprednisolone
Methylprednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Diazoxide {u} (Compound) binds {v} (Gene) ATP1A1
ATP1A1 {u} (Gene) is upregulated by {v} (Compound) Betamethasone
Betamethasone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Diazoxide {u} (Compound) upregulates {v} (Gene) PRKCQ
PRKCQ {u} (Gene) is upregulated by {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Diazoxide {u} (Compound) resembles {v} (Compound) Chlorothiazide
Chlorothiazide {u} (Compound) resembles {v} (Compound) Polythiazide
Polythiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Diazoxide {u} (Compound) upregulates {v} (Gene) P4HTM
P4HTM {u} (Gene) is downregulated by {v} (Compound) Levonorgestrel
Levonorgestrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Diazoxide {u} (Compound) palliates {v} (Disease) hypertension
hypertension {u} (Disease) is treated by {v} (Compound) Nicardipine
Nicardipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Empagliflozin
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Diazoxide (Compound) binds KCNJ11 (Gene) and KCNJ11 (Gene) is bound by Nateglinide (Compound) and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Diazoxide (Compound) binds ATP1A1 (Gene) and ATP1A1 (Gene) is upregulated by Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Diazoxide (Compound) upregulates PRKCQ (Gene) and PRKCQ (Gene) is upregulated by Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Diazoxide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide (Compound) resembles Polythiazide (Compound) and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Diazoxide (Compound) upregulates P4HTM (Gene) and P4HTM (Gene) is downregulated by Levonorgestrel (Compound) and Levonorgestrel may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Diazoxide (Compound) palliates hypertension (Disease) and hypertension (Disease) is treated by Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin